JP Morgan Chase
ERNA icon

JP Morgan Chase’s Eterna Therapeutics ERNA Stock Holding History

JP Morgan Chase’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Hold
0
– -$9 – 7235
2025
Q1 		– Hold
0
– – – 7190
2024
Q4 		– Hold
0
– – – 7283
2024
Q3 		– Hold
0
– – – 7270
2024
Q2 		– Hold
0
– – – 7144
2024
Q1 		– Hold
0
– – – 7100
2023
Q4 		– Hold
0
– – – 7308
2023
Q3 		– Hold
0
– – – 7078
2023
Q2 		– Hold
0
– – – 6767
2023
Q1 		– Hold
0
– – – 6836
2022
Q4 		– Sell
-11
Closed -$15.5K – 6658
2022
Q3 		$21K Sell
11
-96
-90% -$331K ﹤0.01% 5787
2022
Q2 		$416K Sell
107
-3
-3% -$21.5K ﹤0.01% 4677
2022
Q1 		$1.69M Buy
110
+30
+38% +$569K ﹤0.01% 3891
2021
Q4 		$2.51M Buy
80
+77
+2,567% +$4.19M ﹤0.01% 3674
2021
Q3 		$193K Sell
3
-2
-40% -$173K ﹤0.01% 5249
2021
Q2 		$676K Buy
+5
New +$720K ﹤0.01% 4519
2019
Q1 		– Hold
0
– – – 5841
2018
Q4 		– Hold
0
– – – 5742
2016
Q3 		– Hold
0
– -$3K – 4611
2016
Q2 		– Hold
0
– – – 4542

Other funds holding ERNA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return
SCA
Sippican Capital Advisors Boston, Massachusetts $146M AUM 26.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $49B AUM 17.78% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $3.28B AUM 23.66% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase's ERNA Position: Q2 2025 in Review

JP Morgan Chase held its Eterna Therapeutics (ERNA) position steady in Q2 2025 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7235.

JP Morgan Chase first reported a position in ERNA in Q2 2021 and has held it in 6 quarters since. The position peaked at $2.51M in Q4 2021. 9 funds tracked by Wall St. Rank hold ERNA as of Q2 2025.

  • JP Morgan Chase held 0 shares of Eterna Therapeutics worth $0 as of Q2 2025.
  • JP Morgan Chase left its Eterna Therapeutics share count unchanged in Q2 2025.
  • Eterna Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2025, its #7235 holding.
  • JP Morgan Chase first reported a position in Eterna Therapeutics in Q2 2021 and has held it in 6 quarters since.
  • JP Morgan Chase's Eterna Therapeutics position peaked at $2.51M in Q4 2021.
  • 9 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.